Focused Issue on Targeted Therapies in NSCLC: An Evolving Landscape

Posted On 2019-06-21 09:46:31



This focused issue on “Targeted Therapies in NSCLC: An Evolving Landscape” is edited by Dr. Lucio Crinò, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

Dr. Lucio Crinò is Director of Medical Oncology Division, Department of Oncology at the University Hospital of Perugia, Italy. Prior to his current position, Dr. Crinò was Director of Medical Oncology in the Department of Oncology at Bellaria-Maggiore Hospital in Bologna, Italy. He spent 2 years as visiting scientist at the National Cancer Institute in Bethesda, Maryland, USA. His research interests include experimental studies on basic and clinical applied research on lung cancer, including translational research.

Focused issue outline:

  1. EGFR first generation TKIs
    Alex Martinez-Marti, Alejandro Navarro, Enriqueta Felip, Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
  2. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Natalie M. Andrews Wright, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Glenwood D. Goss, The University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada
  3. Liquid biopsy
    Maemondo Makoto, Department of Internal Medicine, Iwate Medical University, Morioka, Japan
  4. New generation ALK inhibitors
    Angelo Delmonte, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  5. Expanding ALK therapeutic indication to early stage NSCLC
    Fabrizio Tabbò and Silvia Novello, Dipartimento di Oncologia, Università degli Studi di Torino, Torino, Italy
  6. Brain metastases in oncogene-driven non-small cell lung cancer
    Tetsuya Mitsudomi, Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
  7. Tyrosine kinase inhibitors (TKIs) interstitial pneumonitis: diagnosis and management
    Caicun Zhou, Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China
  8. Biomarker for personalized immunotherapy
    Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; School of Medicine, South China University of Technology, Guangzhou, China